Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection

Journal of Interferon and Cytokine Research

Volumn 22, Issue 4, 2002, Pages 483-489

  Pianko, Stephen ^a   Blatt, Lawrence M ^a,e   McHutchison, John G ^a   Gordon, Stuart C ^b   Heaton, Shanon ^a   Goodman, Zachary D ^c   Patel, Keyur ^a   Cortese, Cherise M ^d   Brunt, Elizabeth M ^d   Bacon, Bruce R ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

^e Ribozyme Pharmaceutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; IRON; REBETRON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; IRON; LIVER; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

HEPATITIS C VIRUS; RNA VIRUSES; STAPHYLOCOCCUS PHAGE 187;

EID: 0036267134     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900252952271     Document Type: Article

References (44)

1. The prevalence of hepatitis C virus in the United States, 1988 through 1994
2. Liver transplantation for chronic viral hepatitis
3. Estimating future hepatitis C morbidity, mortality, and costs in the United States
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Randomized trial of interferon α2b plus ribavirin for 48 weeks or 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
6. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial
7. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial
8. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
9. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials
10. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
11. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection
12. Measurements of iron status in patients with chronic hepatitis
13. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial
14. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C
15. Response to interferon alpha therapy is influenced by the iron content of the liver
16. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C
17. Response-related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C
18. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
19. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
20. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
21. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C
22. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy
23. A simple technique for measuring storage iron concentrations in formalinised liver samples
24. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: Diagnostic implications
25. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis
26. Iron stores, response to alfa-interferon therapy and effects of iron depletion in chronic hepatitis C
27. Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus
28. Early negative tests for serum HCV RNA as a predictor of sustained response to interferon therapy in patients with chronic hepatitis C
29. The effect of nontransferrin-bound iron on murine T lymphocyte subsets: Analysis by clonal techniques
30. Clonal analysis of the effect of iron on human cytotoxic and proliferating T lymphocytes
31. Iron, oxidative stress and liver fibrogenesis
32. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda
33. The pathology of hepatic iron overload: A free radical-mediated process?
34. Molecular mechanisms of action of ribavirin
35. The antiviral compound ribavirin modulates then T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses
36. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
37. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
38. Prolonged therapy of chronic hepatitis C with ribavirin
39. Ribavirin treatment for patients with chronic hepatitis C: Results of a placebo-controlled study
40. Iron depletion and interferon alpha retreatment is associated with biochemical response in previous hepatitis C non-responders
41. Iron and viral hepatitis
42. Deironization in chronic hepatitis C patients previously non-responsive to interferon improves transaminase activity but not viral activity
43. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial
44. Serum cytokine response to phlebotomy in chronic hepatitis C